Parkinson's Disease (PD)
Conditions
Brief summary
The purpose of the study is to assess the safety, tolerability, and pharmacokinetics of single, ascending doses of ABBV-951 administered as a subcutaneous bolus infusion followed by a continuous subcutaneous infusion in subjects with Parkinson's disease.
Interventions
DRUGABBV-951
ABBV-951 administered by subcutaneous infusion.
Sponsors
AbbVie
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
45 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Subject has a diagnosis of definite idiopathic PD, which is LD responsive, according to the United Kingdom Parkinson's Disease Society Brain Bank Criteria. * Subject must be taking an optimized and stable regimen of oral medications for PD, which has remained stable and unchanged for at least 30 days before dosing in this study. This regimen must include oral carbidopa/levodopa (CD/LD) tablets (e.g., Sinemet). * Females must have negative results for pregnancy tests at screening and prior to confinement. * If male, subject must be surgically sterile or practicing an adequate method of birth control from initial study drug administration until 30 days after last dose of study drug. * Body Mass Index (BMI) is 18.0 to 38.0, inclusive. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
Exclusion criteria
* Receipt of any drug by injection within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study drug administration. * History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis, etc.) or evidence of recent sunburn, acne, scar tissue, tattoo, open wound, branding, or colorations that in the Investigator's opinion would interfere with the infusion of the study drug or could interfere with study assessments. * Use of any medication from the prohibited concomitant therapies. * Subjects with glomerular filtration rate (GFR) less than 45 ml/min/1.73 m2 as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation. * Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to initial study drug administration. * Consideration by the investigator for any reason that the subject is an unsuitable candidate to receive ABBV-951.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve (AUC) of Levodopa | Hour 0-24 | Area under the plasma concentration-time curve following a single infusion of ABBV-951. |
| Adverse Events | 24 hours | Number of participants reporting adverse events |
| Terminal phase elimination rate constant (β) | Up to 72 hours | Apparent terminal phase elimination rate constant (β or Beta) |
| Terminal phase elimination half-life (T1/2) | Up to 72 hours | Terminal phase elimination half-life (t1/2) will be assessed. |
| Maximum Observed Plasma Concentration (Cmax) of Levodopa | Hour 0-24 | Maximum observed plasma concentration of levodopa following a single infusion of ABBV-951. |
| Time to maximum observed plasma concentration (Tmax) of Levodopa | Hour 0-24 | Time to maximum observed plasma concentration of levodopa following a single infusion of ABBV-951. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Corrected QT (QTc) Interval | Up to 76 hours | QT interval adjusted for heart rate. |
Countries
United States
Outcome results
None listed